Precigen, Inc. is a dedicated discovery and clinical-stage biopharmaceutical company advancing gene and cell therapies. The Company’s proprietary technology platforms develops product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders and infectious diseases. It has developed a pipeline of therapies across multiple indications. The Company operates through two segments: Biopharmaceuticals and Exemplar. Biopharmaceuticals segment is primarily comprised of the Company's legal entities of Precigen and ActoBio, as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. Exemplar segment is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar (Exemplar), its wholly owned subsidiary focused on developing research models and services for healthcare research applications.
企業コードPGEN
会社名Precigen Inc
上場日Aug 08, 2013
最高経営責任者「CEO」Dr. Helen Sabzevari, Ph.D.
従業員数143
証券種類Ordinary Share
決算期末Aug 08
本社所在地20374 Seneca Meadows Parkway
都市GERMANTOWN
証券取引所NASDAQ Global Select Consolidated
国United States of America
郵便番号20876
電話番号13015569900
ウェブサイトhttps://precigen.com/
企業コードPGEN
上場日Aug 08, 2013
最高経営責任者「CEO」Dr. Helen Sabzevari, Ph.D.
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし